MyMD Pharmaceuticals Announces Issuance of U.S. Patent Covering Lead Drug Candidate MYMD-1 in a Method of Extending Lifespan
November 23 2021 - 9:25AM
Business Wire
Expands intellectual property portfolio for
lead drug candidate MYMD-1 to 12 U.S. patents
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the
Company”), a clinical stage pharmaceutical company committed to
extending healthy lifespan by delaying aging, announced that the
U.S. Patent and Trademark Office (USPTO) today issued U.S. Patent
11,179,382 B2, titled “Methods of Reversing Normal Aging Process
and Extending Lifespan.” The allowed claims protect the use of
MYMD-1 in a method designed to extend the lifespan of an
individual.
“This patent is a timely addition to our IP portfolio as we
advance toward the launch of our fully funded Phase 2 trial of
MYMD-1 for aging. After a comprehensive review by USPTO, we are
pleased with the broad scope of the granted claims which offer
further protection for our lead drug candidate, which we believe
has the potential to become the first and only FDA-approved
therapeutic solution for delaying aging and prolonging healthy
lifespan,” said Chris Chapman, M.D., President, Director and Chief
Medical Officer of MyMD.
“Our primary focus for MYMD-1 is to slow the aging process,
prevent sarcopenia and frailty, and extend healthy lifespan,” Dr.
Chapman added. “It’s also important to note that MYMD-1 shows
promise in pre-clinical studies as a treatment for immune diseases
including rheumatoid arthritis, multiple sclerosis, and Hashimoto’s
thyroiditis, and as an anti-fibrotic and anti-proliferation
therapeutic.”
The latest patent adds to MyMD’s intellectual property portfolio
of 14 granted patents (12 U.S. and two foreign) covering MYMD-1 in
methods of treating chronic inflammation, autoimmune disorders,
diabetes, multiple sclerosis, viral infections, addictions,
fibrosis, asthma, and other disorders. MyMD also holds two patents
for its synthetic cannabidiol (CBD) derivative Supera-CBD. An
additional 30 patent applications are pending worldwide.
About MYMD-1 Originally developed for autoimmune
diseases, MYMD-1’s primary purpose is to slow the aging process,
prevent sarcopenia and frailty, and extend healthy lifespan.
Because it can cross the blood-brain barrier and gain access to the
central nervous system (CNS), MYMD-1 is also positioned to be a
possible treatment for brain-related disorders. Its mechanism of
action and efficacy in diseases including multiple sclerosis (MS)
and thyroiditis have been studied through collaborations with
several academic institutions. MYMD-1 is also showing promise in
pre-clinical studies as a potential treatment for post- COVID-19
complications and as an anti-fibrotic and anti-proliferation
therapeutic.
MYMD-1 has shown effectiveness in pre-clinical studies in
regulating the immune system by performing as a selective inhibitor
of tumor necrosis factor-alpha (TNF-α), a driver of chronic
inflammation. Unlike other therapies, MYMD-1 has been shown to
selectively block TNF-α when it becomes overactivated in autoimmune
diseases and cytokine storms, but not block it from doing its
normal job of being a first responder to any routine type of
moderate infection. MYMD-1’s ease of oral dosing is another
differentiator compared to currently available TNF-α blockers, all
of which require delivery by injection or infusion. No approved TNF
inhibitor has ever been dosed orally. In addition, the drug is not
immunosuppressive and has not been shown to cause the serious side
effects common with traditional therapies that treat
inflammation.
About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals,
Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company
committed to extending healthy lifespan, is focused on developing
two novel therapeutic platforms that treat the causes of disease
rather than only addressing the symptoms. MYMD-1 is a drug platform
based on a clinical stage small molecule that regulates the immune
system to control TNF-α, which drives chronic inflammation, and
other pro-inflammatory cell signaling cytokines. MYMD-1 is being
developed to delay aging, increase longevity, and treat autoimmune
diseases and COVID-19- associated depression. The Company’s second
drug platform, Supera-CBD, is being developed to treat chronic
pain, addiction and epilepsy. Supera-CBD is a novel synthetic
derivative of cannabidiol (CBD) and is being developed to address
and improve upon the rapidly growing CBD market, which includes
both FDA approved drugs and CBD products not currently regulated as
drugs. For more information, visit www.mymd.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release may contain forward-looking statements. These
forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause actual results,
performance or achievements to be materially different from any
expected future results, performance, or achievements.
Forward-looking statements speak only as of the date they are made
and none of MyMD nor its affiliates assume any duty to update
forward-looking statements. Words such as "anticipate," "believe,"
"could," "estimate," "expect," "may," "plan," "will," "would'' and
other similar expressions are intended to identify these
forward-looking statements. Important factors that could cause
actual results to differ materially from those indicated by such
forward-looking statements include, without limitation: the timing
of, and MyMD’s ability to, obtain and maintain regulatory approvals
for clinical trials of MyMD’s pharmaceutical candidates; the timing
and results of MyMD’s planned clinical trials for its
pharmaceutical candidates; the amount of funds MyMD requires for
its pharmaceutical candidates; increased levels of competition;
changes in political, economic or regulatory conditions generally
and in the markets in which MyMD operates; MyMD’s ability to retain
and attract senior management and other key employees; MyMD’s
ability to quickly and effectively respond to new technological
developments; MyMD’s ability to protect its trade secrets or other
proprietary rights, operate without infringing upon the proprietary
rights of others and prevent others from infringing on MyMD’s
proprietary rights; and the impact of the ongoing COVID-19 pandemic
on MyMD’s results of operations, business plan and the global
economy. A discussion of these and other factors with respect to
MyMD is set forth in the Quarterly Report on Form 10-Q for the
quarterly period ended September 30, 2021, filed by MyMD on
November 12, 2021 (as amended on November 15, 2021).
Forward-looking statements speak only as of the date they are made
and MyMD disclaims any intention or obligation to revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211123005524/en/
MyMD Contact: Robert Schatz (646) 421-9523
rschatz@mymd.com www.mymd.com
MyMD Pharmaceuticals (NASDAQ:MYMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MyMD Pharmaceuticals (NASDAQ:MYMD)
Historical Stock Chart
From Sep 2023 to Sep 2024